Chronic Lymphocytic Leukemia | Specialty

Dr. Fakhri on the Use of PI3K Inhibitors in Relapsed/Refractory CLL

January 24th 2020

Bita Fakhri, MD, MPH, assistant professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of PI3K inhibitors in relapsed/refractory chronic lymphocytic leukemia (CLL).

Dr. Sharman on the Design of the ELEVATE-TN Trial in CLL

January 22nd 2020

Jeff Sharman, MD, discusses the design of the phase III ELEVATE-TN trial in patients with previously untreated chronic lymphocytic leukemia.

Advances Continue at Rapid Pace in CLL Paradigm

January 21st 2020

Bita Fakhri, MD, discusses data from several recent trials in chronic lymphocytic leukemia and focused on other regimens moving through the pipeline.

Dr. Pagel on the ELEVATE-TN Trial in CLL

January 21st 2020

John M. Pagel, MD, PhD, discusses the phase III ELEVATE-TN trial in chronic lymphocytic leukemia.

Dr. Fakhri on Tumor Lysis Syndrome Associated With Venetoclax/Obinutuzumab in CLL

January 16th 2020

Bita Fakhri, MD, MPH, discusses concern over the tumor lysis syndrome that occurred in the CLL14 trial that looked at patients with previously untreated chronic lymphocytic leukemia.

Dr. Woyach on Ongoing Research With BTK Inhibitors in CLL

January 14th 2020

Jennifer Woyach, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center–James, discusses ongoing research with BTK inhibitors in chronic lymphocytic leukemia (CLL).

Long-Term Follow-Up of Acalabrutinib in Patients With MCL and CLL

January 10th 2020

Kellie Ryan, MPH, discusses the importance of long-term follow-up with acalabrutinib in patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).

Dr. Fakhri on Selecting the Optimal Treatment in CLL

January 10th 2020

Bita Fakhri, MD, MPH, discusses considerations in selecting the optimal treatment in chronic lymphocytic leukemia.

Zanubrutinib Faces Off Against Ibrutinib in CLL Trial

January 8th 2020

Armed with the knowledge that inhibition of the Bruton tyrosine kinase is an effective approach in B-cell malignancies, investigators will explore the efficacy of the second-generation BTK inhibitor, zanubrutinib, in 2 leukemia and lymphoma subtypes.

Woyach Highlights Progress and Next Steps in CLL Paradigm

January 8th 2020

Jennifer A. Woyach, MD, discusses the evolving treatment paradigm and sequencing challenges in chronic lymphocytic leukemia.

Dr. Leslie on Real-World Outcomes of Patients With CLL Treated With Acalabrutinib

January 8th 2020

Lori A. Leslie, MD, discusses a retrospective analysis of real-world patients with chronic lymphocytic leukemia who were treated with acalabrutinib (Calquence).

Dr. Woyach on the Results of the ELEVATE-TN Trial in CLL

January 7th 2020

Jennifer Woyach, MD, discusses the results of the ELEVATE-TN trial in patients with treatment-naïve chronic lymphocytic leukemia.

Dr. Woyach on Frontline Treatment Options in CLL

January 3rd 2020

Jennifer Woyach, MD, discusses frontline treatment options for patients with chronic lymphocytic leukemia.

Final Thoughts From ASH 2019 in CLL

December 24th 2019

Novel Combinations in Development for CLL

December 24th 2019

PI3K Inhibitors in R/R CLL

December 24th 2019

BTK Inhibitors in R/R CLL

December 24th 2019

Venetoclax in R/R CLL

December 24th 2019

Progression on Frontline Ibrutinib in CLL

December 24th 2019

Resistance Mechanisms Associated With BTK Inhibitors

December 24th 2019